Scientific Reports (Mar 2022)
Anti-SARS-CoV-2 equine F (Ab′)2 immunoglobulin as a possible therapy for COVID-19
- Viviane Fongaro Botosso,
- Soraia Attie Calil Jorge,
- Renato Mancini Astray,
- Ana Marcia de Sá Guimarães,
- Monica Beatriz Mathor,
- Patrícia dos Santos de Carneiro,
- Edison Luiz Durigon,
- Dimas Covas,
- Danielle Bruna Leal de Oliveira,
- Ricardo das Neves Oliveira,
- Durvanei Augusto Maria,
- Silas Fernandes Eto,
- Neuza Maria Frazatti Gallina,
- Giselle Pidde,
- Carla Cristina Squaiella-Baptistão,
- Dilza Trevisan Silva,
- Isadora Maria Villas-Boas,
- Dayanne Carla Fernandes,
- Aline Vivian Vatti Auada,
- Alexandre Campos Banari,
- Antônio Francisco de Souza Filho,
- Camila Bianconi,
- Carla Lilian de Agostini Utescher,
- Denise Cristina André Oliveira,
- Douglas Oscar Ceolin Mariano,
- Flávia Ferreira Barbosa,
- Giuliana Rondon,
- Josana Kapronezai,
- Juliana Galvão da Silva,
- Mauricio Barbugiani Goldfeder,
- Priscila Comone,
- Regis Edgar Castilho Junior,
- Taiana Tainá Silva Pereira,
- Fan Hui Wen,
- Denise V. Tambourgi,
- Ana Marisa Chudzinski-Tavassi
Affiliations
- Viviane Fongaro Botosso
- Virology Laboratory, Butantan Institute
- Soraia Attie Calil Jorge
- Viral Biotechnology Laboratory, Butantan Institute
- Renato Mancini Astray
- Multipurpose Laboratory, Butantan Institute
- Ana Marcia de Sá Guimarães
- Microbiology Department, Biomedical Science Institute, University of São Paulo
- Monica Beatriz Mathor
- Institute for Energy and Nuclear Research
- Patrícia dos Santos de Carneiro
- Quality Control, Butantan Institute
- Edison Luiz Durigon
- Microbiology Department, Biomedical Science Institute, University of São Paulo
- Dimas Covas
- Direction, Butantan Institute
- Danielle Bruna Leal de Oliveira
- Virology Laboratory, Butantan Institute
- Ricardo das Neves Oliveira
- Bioindustrial Center, Butantan Institute
- Durvanei Augusto Maria
- Development and Innovation Laboratory, Butantan Institute
- Silas Fernandes Eto
- Development and Innovation Laboratory, Butantan Institute
- Neuza Maria Frazatti Gallina
- Viral Vaccines Pilot Laboratory, Butantan Institute
- Giselle Pidde
- Immunochemistry Laboratory, Butantan Institute
- Carla Cristina Squaiella-Baptistão
- Immunochemistry Laboratory, Butantan Institute
- Dilza Trevisan Silva
- Center of Excellence in New Target Discovery (CENTD), Special Laboratory
- Isadora Maria Villas-Boas
- Immunochemistry Laboratory, Butantan Institute
- Dayanne Carla Fernandes
- Immunochemistry Laboratory, Butantan Institute
- Aline Vivian Vatti Auada
- Bioindustrial Center, Butantan Institute
- Alexandre Campos Banari
- Microbiology Department, Biomedical Science Institute, University of São Paulo
- Antônio Francisco de Souza Filho
- Microbiology Department, Biomedical Science Institute, University of São Paulo
- Camila Bianconi
- Bioindustrial Center, Butantan Institute
- Carla Lilian de Agostini Utescher
- Virology Laboratory, Butantan Institute
- Denise Cristina André Oliveira
- Virology Laboratory, Butantan Institute
- Douglas Oscar Ceolin Mariano
- Bioindustrial Center, Butantan Institute
- Flávia Ferreira Barbosa
- Multipurpose Laboratory, Butantan Institute
- Giuliana Rondon
- Development and Innovation Laboratory, Butantan Institute
- Josana Kapronezai
- Virology Laboratory, Butantan Institute
- Juliana Galvão da Silva
- Quality Control, Butantan Institute
- Mauricio Barbugiani Goldfeder
- Development and Innovation Laboratory, Butantan Institute
- Priscila Comone
- Bioindustrial Center, Butantan Institute
- Regis Edgar Castilho Junior
- Development and Innovation Laboratory, Butantan Institute
- Taiana Tainá Silva Pereira
- Microbiology Department, Biomedical Science Institute, University of São Paulo
- Fan Hui Wen
- Bioindustrial Center, Butantan Institute
- Denise V. Tambourgi
- Immunochemistry Laboratory, Butantan Institute
- Ana Marisa Chudzinski-Tavassi
- Development and Innovation Laboratory, Butantan Institute
- DOI
- https://doi.org/10.1038/s41598-022-07793-1
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 17
Abstract
Abstract The new outbreak of coronavirus disease 2019 (COVID-19) has infected and caused the death of millions of people worldwide. Intensive efforts are underway around the world to establish effective treatments. Immunoglobulin from immunized animals or plasma from convalescent patients might constitute a specific treatment to guarantee the neutralization of the virus in the early stages of infection, especially in patients with risk factors and a high probability of progressing to severe disease. Worldwide, a few clinical trials using anti-SARS-CoV-2 immunoglobulins from horses immunized with the entire spike protein or fragments of it in the treatment of patients with COVID-19 are underway. Here, we describe the development of an anti-SARS-CoV-2 equine F(ab′)2 immunoglobulin using a newly developed SARS-CoV-2 viral antigen that was purified and inactivated by radiation. Cell-based and preclinical assays showed that the F(ab′)2 immunoglobulin successfully neutralizes the virus, is safe in animal models, and reduces the severity of the disease in a hamster model of SARS-CoV-2 infection and disease.
